BioCryst Pharmaceuticals (BCRX) News Today → get a piece of the profit from this land (From True Market Insiders) (Ad) Free BCRX Stock Alerts $6.28 -0.19 (-2.94%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 18 at 2:26 AM | americanbankingnews.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Rating of "Buy" from AnalystsMay 16 at 1:39 PM | insidertrades.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Director Steven K. Galson Buys 21,940 SharesMay 16 at 1:38 AM | americanbankingnews.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up After Insider Buying ActivityMay 15, 2024 | finance.yahoo.comInsider Buying: CFO Anthony Doyle Acquires Shares of BioCryst Pharmaceuticals Inc (BCRX)May 15, 2024 | finance.yahoo.comInsider Buying: Charles Gayer Acquires 30,000 Shares of BioCryst Pharmaceuticals Inc (BCRX)May 15, 2024 | finance.yahoo.comDirector Steven Galson Acquires 21,940 Shares of BioCryst Pharmaceuticals Inc (BCRX)May 15, 2024 | finance.yahoo.comInsider Buying: Chief R&D Officer Helen Thackray Acquires 30,000 Shares of BioCryst ...May 15, 2024 | marketbeat.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up on Insider Buying ActivityBioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up on Insider Buying ActivityMay 15, 2024 | seekingalpha.comBioCryst Pharmaceuticals, T2 Biosystems, Annovis Bio among healthcare moversMay 15, 2024 | marketbeat.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Director Steven K. Galson Purchases 21,940 SharesBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) Director Steven K. Galson purchased 21,940 shares of BioCryst Pharmaceuticals stock in a transaction dated Monday, May 13th. The shares were acquired at an average cost of $5.49 per share, with a total value of $120,450.60. Following the transaction, the director now directly owns 51,551 shares in the company, valued at $283,014.99. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.May 14, 2024 | globenewswire.comBioCryst to Present New Data at 2024 Meeting of the European Academy of Allergy and Clinical ImmunologyMay 13, 2024 | markets.businessinsider.comBiocryst Pharma's Orladeyo Approved In Mexico For Hereditary Angioedema AttacksMay 13, 2024 | globenewswire.comORLADEYO® (berotralstat) Approved in MexicoMay 10, 2024 | americanbankingnews.comHC Wainwright Comments on BioCryst Pharmaceuticals, Inc.'s Q2 2024 Earnings (NASDAQ:BCRX)May 9, 2024 | finance.yahoo.comAnalysts Are Updating Their BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Estimates After Its First-Quarter ResultsMay 9, 2024 | finance.yahoo.comBioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO® (berotralstat)May 9, 2024 | globenewswire.comBioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO® (berotralstat)May 9, 2024 | marketbeat.comEquities Analysts Issue Forecasts for BioCryst Pharmaceuticals, Inc.'s Q2 2024 Earnings (NASDAQ:BCRX)BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Research analysts at HC Wainwright upped their Q2 2024 earnings per share (EPS) estimates for BioCryst Pharmaceuticals in a research report issued on Tuesday, May 7th. HC Wainwright analyst A. Fein now forecasts that the biotechnology cMay 9, 2024 | americanbankingnews.comFY2028 EPS Estimates for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Reduced by AnalystMay 8, 2024 | marketbeat.comFY2028 EPS Estimates for BioCryst Pharmaceuticals, Inc. Decreased by Analyst (NASDAQ:BCRX)BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Stock analysts at HC Wainwright reduced their FY2028 earnings per share (EPS) estimates for BioCryst Pharmaceuticals in a report issued on Tuesday, May 7th. HC Wainwright analyst A. Fein now anticipates that the biotechnology company wiMay 7, 2024 | markets.businessinsider.comBuy Rating for BioCryst’s Orladeyo: Poised for Pediatric Market Growth and Continued HAE Market PenetrationMay 7, 2024 | bizjournals.comWhy this RTP public company expects big revenue gains in 2024May 7, 2024 | finance.yahoo.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q1 2024 Earnings Call TranscriptMay 7, 2024 | marketbeat.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target Raised to $15.00 at JMP SecuritiesJMP Securities boosted their price target on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a "market outperform" rating in a report on Tuesday.May 7, 2024 | marketbeat.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Up 5.5% Following Better-Than-Expected EarningsBioCryst Pharmaceuticals (NASDAQ:BCRX) Trading 5.5% Higher Following Strong EarningsMay 7, 2024 | marketbeat.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Announces Quarterly Earnings Results, Beats Expectations By $0.06 EPSBioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) released its earnings results on Monday. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.06. The company had revenue of $92.80 million during the quarter, compared to analyst estimates of $85.62 million. During the same period in the previous year, the firm posted ($0.28) EPS. The company's revenue for the quarter was up 34.9% on a year-over-year basis.May 7, 2024 | marketbeat.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Receives Buy Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and set a $30.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday.May 7, 2024 | finance.yahoo.comBioCryst Pharmaceuticals Inc (BCRX) Q1 2024 Earnings Call Transcript Highlights: Key Financial ...May 7, 2024 | globenewswire.comBioCryst to Present at Upcoming Investor ConferencesMay 7, 2024 | seekingalpha.comBioCryst: Estimate-Beating Q1 But Risks Are ConsiderableMay 7, 2024 | finance.yahoo.comQ1 2024 BioCryst Pharmaceuticals Inc Earnings CallMay 6, 2024 | fool.comWhy BioCryst Pharmaceuticals Vaulted Nearly 20% Higher on MondayMay 6, 2024 | marketbeat.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up to $4.45BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up to $4.45May 6, 2024 | marketwatch.comBioCryst Pharma Shares Jump on Strong 1QMay 6, 2024 | msn.comBioCryst Pharmaceuticals 'Fantastic' Q1 Earnings Rides On Outstanding Orladeyo PerformanceMay 6, 2024 | markets.businessinsider.comBioCryst Pharmaceuticals Reports Q1 Loss, Tops Revenue EstimatesMay 6, 2024 | fool.comBioCryst Pharmaceuticals (BCRX) Q1 2024 Earnings Call TranscriptMay 6, 2024 | marketbeat.comBioCryst Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:BCRX)BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) was the target of unusually large options trading activity on Monday. Traders purchased 2,478 call options on the company. This is an increase of 59% compared to the average daily volume of 1,554 call options.May 6, 2024 | finanznachrichten.deBioCryst Pharmaceuticals, Inc.: BioCryst Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 6, 2024 | finance.yahoo.comBioCryst Pharmaceuticals Reports Strong Q1 2024 Results, Exceeding Analyst Revenue ForecastsMay 6, 2024 | seekingalpha.comBioCryst Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call PresentationMay 6, 2024 | seekingalpha.comBioCryst Pharmaceuticals beats top-line and bottom-line estimates; updates FY24 outlookMay 6, 2024 | globenewswire.comBioCryst Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 6, 2024 | marketbeat.comFisher Asset Management LLC Has $17.28 Million Stock Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Fisher Asset Management LLC cut its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 9.5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,884,097 shares of the biotechnology company's stock aMay 3, 2024 | finanznachrichten.deBioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 3, 2024 | globenewswire.comBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1, 2024 | marketbeat.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Up 6.1%BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Up 6.1%May 1, 2024 | marketbeat.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Short Interest UpdateBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) saw a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 34,390,000 shares, a growth of 6.6% from the March 31st total of 32,250,000 shares. Based on an average daily volume of 3,130,000 shares, the short-interest ratio is currently 11.0 days.April 29, 2024 | marketbeat.comabrdn plc Takes Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)abrdn plc acquired a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 504,528 shares of the biotechnology company's stock, valuedApril 22, 2024 | finance.yahoo.comWith 80% ownership, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) boasts of strong institutional backing Get BioCryst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address The CHIPS Act Motherlode (Ad)If you haven’t heard yet, the CHIPS Act is the US government pouring $280 BILLION into the manufacturing of US semiconductors. A lot of companies will make a fortune from this. Click here to see my #1 investment for 2024. BCRX Media Mentions By Week BCRX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BCRX News Sentiment▼1.110.42▲Average Medical News Sentiment BCRX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BCRX Articles This Week▼164▲BCRX Articles Average Week Get BioCryst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: NVAX News Today SRRK News Today CGEM News Today AUTL News Today IMTX News Today PROK News Today FDMT News Today RLAY News Today VIR News Today MESO News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BCRX) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersBuy this small stock before coming AI Tidal WaveChaikin AnalyticsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingDems have chosen Biden replacement?Paradigm PressForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersA letter is coming from the "Bureau of the Fiscal Service".Stansberry ResearchHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCryst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
